血栓通联合参麦注射液治疗老年非ST段抬高型急性心肌梗死的临床分析

摘要

目的：探讨血栓通联合参麦注射液治疗老年非ST段抬高型急性心肌梗死的临床疗效。方法分析我院2014年3月至2016年4月收治的126例老年非ST段抬高型急性心肌梗死患者临床资料，依据治疗措施不同进行分组，对照组63例和观察组63例，观察两组老年非ST段抬高型急性心肌梗死患者抢救成功率、病死率、心肌梗死复发率情况。结果观察组老年非ST段抬高型急性心肌梗死患者抢救成功率96.8%高于对照组77.8%，病死率1.6%、心肌梗死复发率1.6%均低于对照组9.5%、12.7%，P<0.05，差异均有统计学意义。结论血栓通联合参麦注射液治疗老年非ST段抬高型急性心肌梗死临床治疗效果明显，预后良好，值得临床推广应用。%Objective To approach clinical result of treatment agedness no STEMI AMI by Xueshuantong compared with shenmai injection.Method The 126 cases clinical data of agedness no STEMI AMI patients in our hospital from 2014.3 to 2016.4 were analyzed, which was to be divided into two groups by different treatment methods, control group 63 cases and detection group 63 cases.Result The rescue success rate 96.8% of detection group no STEMI AMI patients were higher than control group 77.8%, death rate 9.5%, myocardial infarction recurrence 12.7% were lower than control group1.6%, 1.6%,P<0.05, the difference were statistical significance.Conclusion The clinical result of treatment agedness no STEMI AMI by Xueshuantong compared with shenmai injection are obviously,prognosis is good, which is to be used.